KraneShares MSCI All China Health Care Index ETF (KURE)
| Assets | $217.15M |
| NAV | $37.12 |
| Expense Ratio | 0.65% |
| PE Ratio | 37.27 |
| Shares Out | 5.85M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 27, 2019 |
| 1-Year Return | - |
| Volume | 18,718 |
| Open | 36.94 |
| Previous Close | 37.16 |
| Day's Range | 36.75 - 37.16 |
| 52-Week Low | 32.60 |
| 52-Week High | 47.69 |
| Beta | 0.60 |
| Holdings | 98 |
| Inception Date | Feb 1, 2018 |
About KURE
The investment seeks to provide investment results that, before fees and expenses, track the price and yield performance of the MSCI China All Shares Health Care 10/40 Index. The fund will invest at least 80% of its total assets in components of the underlying index, depositary receipts, representing such components and securities underlying depositary receipts in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Top 10 Holdings
43.08% of assets| Name | Symbol | Weight |
|---|---|---|
| WuXi Biologics (Cayman) Inc | 2269.HK | 9.44% |
| Shenzhen Mindray Bio-Medical Electronics Co Ltd | 300760.SZ | 5.69% |
| Wuxi AppTec Co Ltd Class A | 603259.SS | 4.82% |
| BeiGene | BGNE | 4.45% |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 600276.SS | 3.88% |
| Aier Eye Hospital Group Co Ltd | 300015.SZ | 3.60% |
| Chongqing Zhifei Biological Products Co Ltd | 300122.SZ | 2.98% |
| CSPC Pharmaceutical Group Ltd | 1093.HK | 2.87% |
| Innovent Biologics Inc | 1801.HK | 2.79% |
| Zhangzhou Pientzehuang Pharmaceutical Co Ltd | 600436.SS | 2.56% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2020 | $0.000109 | Dec 31, 2020 |
| Dec 27, 2019 | $0.057325 | Dec 31, 2019 |
| Dec 26, 2018 | $0.039344 | Dec 28, 2018 |
News
A KURE-All for Bland Healthcare Exposure
In some form or fashion, hundreds of exchange traded funds offer exposure to Chinese equities. As the world's second-largest country has evolved, so have the related ETF offerings.
Healthcare Gains Drive Chinese Stocks Even Higher
Asian markets ended last week up, buoyed in part by a rally in healthcare firms, according to Reuters. The blue-chip CSI300 Index, which tracks the top 300 stocks traded on the Shenzhen Stock Exchange a...
Cover All the Hot Bases in Chinese Equity with This Model Portfolio
ETF investors looking for growth and innovation in China, can turn to the KraneShares Krane China Innovation Strategy. The strategy consists of a model portfolio that seeks to provide investors exposure...
5 Top-Performing ETFs of Last Week
Wall Street was downbeat last week on inflationary concerns and some downbeat economic data points.
Best-Performing ETF Areas of Last Week
Last week was slightly downbeat for Wall Street on talks of a capital gain tax hike with three big U.S. indexes remaining in the red.
Is Chinese Healthcare the Miracle KURE for Your Portfolio?
In the United States, healthcare is a dynamic sector home to defensive value stocks, disruptive growth names, and plenty of in-between. China offers a comparable level of healthcare dynamism, which inve...
Best Pharmaceutical ETFs for Q2 2021
The best pharmaceutical ETFs for Q2 2021 are KURE, MJJ, and POTX.
Top ETF Areas of Last Week
The markets rallied because Biden started his term by signing a number of executive orders to counter the ill effects of the COVID-19 pandemic, empower environmental protection initiatives and roll back...
Best Healthcare ETFs for Q1 2021
The best healthcare ETFs for Q1 2021 are ARKG, PTH, and KURE.
Best Pharmaceutical ETFs for Q1 2021
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Chinese stocks have biggest gains in 3 months
Yahoo Finance's Tom Belger reports on the latest stock news from China and Europe.
Best Healthcare ETFs for Q4 2020
The best healthcare ETFs for Q4 2020 are ARKG, KURE, and PTH.
Best Pharmaceutical ETFs for Q4 2020
The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.
Top 10 Sector ETFs on the Market Today
Sector ETFs and industry funds are different. The 11 sectors addressed in the S&P 500 are as follows (in order of weight in the index): technology, healthcare, consumer discretionary, communication serv...
5 Reasons to Bet on China ETFs
The Chinese economy returned to growth in the second quarter of 2020. This along with PBOC's targeted policy easing and China's solid tech industry make China investing winners in the recent trading ses...
7 Emerging Markets ETFs for Adventurous Investors
In theory, blaming the emerging markets malaise on China because the country was the initial epicenter of the coronavirus appears to make sense. However, that argument doesn't hold water because the MSC...
3 Best Country ETFs of 1H That Survived the Pandemic
While most the countries' stocks have been beaten down badly in the pandemic, some still managed to trade in green for the first half of the year.
China Healthcare ETF (KURE) Hits New 52-Week High
The fund hit a 52-week high lately. Can this go further higher?
Best Performing Pharmaceutical ETFs for Q3 2020
The best pharmaceutical ETFs for Q3 2020 are KURE, XPH, and PPH.
Best-Performing Healthcare ETFs for Q3 2020
The best Healthcare ETFs for Q3 2020 are ARKG, KURE, and PTH.
Healthcare ETFs Are Shining in China, Too
Healthcare stocks and ETFs are outperforming the broader market this year, but as the KraneShares MSCI All China Health Care Indes ETF (KURE) proves, that theme isn’t confined to the U.S. KURE invests i...